Vinflunine oral pharmacokinetics and absolute bioavailability of soft and hard gelatin capsules: results of two phase I trials.

@article{Delord2012VinflunineOP,
  title={Vinflunine oral pharmacokinetics and absolute bioavailability of soft and hard gelatin capsules: results of two phase I trials.},
  author={Jean Pierre Delord and Jaafar Bennouna and Lo{\"i}c Mourey and Jo{\"e}l Bougaret and Maud Brandely-Talbot and Pierre Jean Ferr{\'e}},
  journal={Clinical pharmacokinetics},
  year={2012},
  volume={51 6},
  pages={357-64}
}
BACKGROUND Vinflunine is a new-generation microtubule inhibitor, which is currently registered in Europe and in some countries elsewhere as an intravenous formulation for the second-line treatment of transitional urothelial cell carcinoma. On the basis of favourable non-clinical results, the clinical development of an oral formulation was initiated. OBJECTIVE The absolute oral bioavailability was investigated in patients through two consecutive trials: the first trial used soft gelatin… CONTINUE READING